Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.

Article  PubMed  Google Scholar 

Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023;10:334.

Article  PubMed  PubMed Central  Google Scholar 

Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53.

Article  PubMed  PubMed Central  Google Scholar 

Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S (2015) Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results of NCIC CTG MA. 31. J Clin Oncol 33: 1574–1583

Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sawyers CLJC (2019) Herceptin: a first assault on oncogenes that launched a revolution. 179:8–12

Elster N, Collins DM, Toomey S, Crown J, Eustace AJ, Hennessy BT. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Res Treat. 2015;149:5–15.

Article  PubMed  CAS  Google Scholar 

Zhang Q, Sakamoto K, Wagner K-UJM and endocrinology c (2014) D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells 382:583–592

Belső N, Gubán B, Manczinger M, Kormos B, Bebes A, Németh I, Veréb Z, Széll M, Kemény L, Bata-Csörgő ZJEcr (2019) Differential role of D cyclins in the regulation of cell cycle by influencing Ki67 expression in HaCaT cells 374:290–303

Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14:348–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mendelsohn AR, Hamer JD, Wang ZB, Brent R. Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. Proc Natl Acad Sci. 2002;99:6871–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Boonen GJ, van Oirschot BA, van Diepen A, Mackus WJ, Verdonck LF, Rijksen G, Medema RH. Cyclin D3 regulates proliferation and apoptosis of leukemic T cell lines. J Biol Chem. 1999;274:34676–82.

Article  PubMed  CAS  Google Scholar 

Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL and Kurzrock RJMct. Cell-cycle gene alterations in 4,864 tumors analyzed by next-generation sequencing: implications for targeted therapeutics. 2016; 15: 1682–1690.

discovery APGCJC (2017) AACR Project GENIE: powering precision medicine through an international consortium7:818–831

Chi Y, Huang S, Liu M, Guo L, Shen X, Wu J. Cyclin D3 predicts disease-free survival in breast cancer. Cancer Cell Int. 2015;15:89.

Article  PubMed  PubMed Central  Google Scholar 

Gharbi SI, Pelletier LA, Espada A, Gutiérrez J, Sanfeliciano SMG, Rauch CT, Ganado MP, Baquero C, Zapatero E, Zhang A, Benach J, Russell AM, Cano L, Gomez S, Broughton H, Pulliam N, Perez CM, Torres R, Debets MF, de Dios A, Puig O, Hilgers MT, Lallena MJ. Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy. NPJ Breast Cancer. 2022;8:126.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cascetta KP, Poulikakos P, Shapiro CL, Bhardwaj AS, Fasano J, Irie H, Klein P, Goel A, Kalinsky K, Adams S, Andreopoulou E, Jaffer S, Ru M, Tiersten A (2018) A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer. J Clin Oncol 36:TPS1103-TPS1103

Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A. Palbociclib and Trastuzumab in HER2-positive advanced breast cancer: results from the Phase II SOLTI-1303 PATRICIA trial. Clin Cancer Res. 2020;26:5820–9.

Article  PubMed  CAS  Google Scholar 

Varshavsky AJA (2017) The ubiquitin system, autophagy, and regulated protein degradation 86:123–128

Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hill S, Reichermeier K, Scott DC, Samentar L, Coulombe-Huntington J, Izzi L, Tang X, Ibarra R, Bertomeu T, Moradian AJE (2019) Robust cullin-RING ligase function is established by a multiplicity of poly-ubiquitylation pathways 8:e51163

Chen Z, Sui J, Zhang F, Zhang C. Cullin family proteins and tumorigenesis: genetic association and molecular mechanisms. J Cancer. 2015;6:233–42.

Article  PubMed  PubMed Central  Google Scholar 

Schwechheimer CJCoipb (2018) NEDD8—its role in the regulation of Cullin-RING ligases 45:112–119

Jang S-M, Redon CE, Thakur BL, Bahta MK, Aladjem MIJE, Medicine M (2020) Regulation of cell cycle drivers by Cullin-RING ubiquitin ligases 1–15

Qie S, Diehl JA (2020) Cyclin D degradation by E3 ligases in cancer progression and treatment. Semin Cancer Biol

Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, Cai Z, Zhu M, Li Q, Li Y, Wang J, Liu Y, Wu Z, Song E, Liu Q. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11:5513.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang Z, Ruan B, Jin Y, Zhang Y, Li J, Zhu L, Xu W, Feng L, Jin H, Wang X. Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer. Oncotarget. 2016;7:79494–502.

Article  PubMed  PubMed Central  Google Scholar 

Feldman RR, Correll CC, Kaplan KB, Deshaies RJ. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell. 1997;91:221–30.

Article  PubMed  CAS  Google Scholar 

Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 1997;91:209–19.

Article  PubMed  CAS  Google Scholar 

Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D (1999) Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–6.

Article  PubMed  CAS  Google Scholar 

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29:255–69.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30:2585–92.

Article  PubMed  CAS  Google Scholar 

Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK. TBCRC023: a randomized Phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer. Clin Cancer Res. 2020;26:821–7.

Article  PubMed  CAS  Google Scholar 

Choi HJ, Jin S, Cho H, Won HY, An HW, Jeong GY, Park YU, Kim HY, Park MK, Son T, Min KW, Jang KS, Oh YH, Lee JY, Kong G. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. EMBO Rep. 2019;20:e48058.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, García-Conde J, Baselga J, Clinton GM. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006;12:424–31.

Article  PubMed  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

Article  PubMed  CAS  Google Scholar 

Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci. 2011;108:3761–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Can Res. 2002;62:4132–41.

CAS